Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781336 | 0.90 | CHRNB2 (0.36) | CHRNB2CHRNA4ALDH1A1MKNK1MKNK2 | |
| SCHEMBL5392162 | 0.77 | ORAI1 (0.38) | — | |
| SCHEMBL11000922 | 0.68 | HTR2C (0.42) | ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3788330 | 0.67 | CHRNB2 (0.33) | CHRNB2CHRNA4ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL655078 | 0.66 | HTR3A (0.39) | CYP2A6 | |
| Piperazine SCHEMBL28287836 | 0.63 | CHRNB2 (0.46) | CHRNB2CHRNA4ALDH1A1NISCHCYP1A2 | |
| Piperazine SCHEMBL28208205 | 0.63 | MEN1 (0.47) | CHRNB2CHRNA4ALDH1A1MKNK1MKNK2 | |
| 3-Methylpyridine SCHEMBL27313811 | 0.63 | CHRNB2 (0.47) | CHRNB2CHRNA4ALDH1A1NISCHCYP1A2 | |
| Piperazine SCHEMBL4431711 | 0.63 | CHRNB2 (0.46) | CHRNB2CHRNA4ALDH1A1NISCHCYP1A2 | |
| SCHEMBL3538787 | 0.63 | CHRNB2 (0.87) | CHRNB2CHRNA4ALDH1A1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261285-A1 | Tetrahydropyran derivatives and their use as therapeutic agents | DIRAT OLIVIER | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261285-A1 | Tetrahydropyran derivatives and their use as therapeutic agents | GRPR, GRM5, GRM6 | CHRNB2 2038/4885CHRNA4 912/4885ALDH1A1 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.